Human noroviruses are the primary cause of epidemic and sporadic acute gastroenteritis. The worldwide high morbidity and mortality associated with norovirus infections, particularly among the elderly, immunocompromised patients and children, constitute a serious public health concern. There are currently no approved human vaccines or norovirus-specific small-molecule therapeutics or prophylactics. Norovirus 3CL protease has recently emerged as a potential therapeutic target for the development of anti-norovirus agents. We hypothesized that the S 4 subsite of the enzyme may provide an effective means of designing potent and cell permeable inhibitors of the enzyme. We report herein the structure-guided exploration and exploitation of the S 4 subsite of norovirus 3CL protease in the design and synthesis of effective inhibitors of the protease.
Introduction
Human noroviruses belong to the family Caliciviridae and are the leading cause of acute gastroenteritis worldwide [1] [2] . They are associated with high morbidity and a heavy economic burden [3] [4] [5] . In developing countries the mortality rate among children <5 years old due to diarrheal disease caused by noroviruses is estimated to account for 71,000 deaths annually [6] [7] [8] . Combating norovirus infections presents a challenge because of the facile foodborne and waterborne transmission of noroviruses, as well as their high genetic diversity and environmental stability [9] [10] . The problem is further exacerbated by the current lack of diagnostics and norovirus-specific therapeutics and prophylactics, or vaccines. Thus, there is an urgent and unmet medical need for the discovery and development of anti-norovirus small-molecule therapeutics and prophylactics [11] [12] [13] [14] , as well as effective vaccines [15] [16] .
Both viral and host factors can in principle serve as a launching pad for the discovery of anti-norovirus therapeutics [11] [12] [13] [14] [17] [18] [19] [20] . Prominent viral targets that are particularly wellsuited as targets for anti-noroviral drug development include the viral-encoded 3CL protease (3CLpro) and RNA dependent RNA polymerase (RdRp) because of the essential roles they play in viral replication [18] . Following translation of the viral genome, the viral polyprotein is cleaved by 3CLpro, a cysteine protease with a prototypical catalytic triad (Cys 139, His30, Glu54) and a strong preference for a P 1 Gln (or Glu) residue [21] , to generate structural and nonstructural proteins [22] [23] [24] Norovirus 3CLpro has been the focus of intense investigations and an array of inhibitors of 3CLpro that display anti-norovirus activity have been reported [11] [12] [13] [14] 19] , including peptidyl [25] [26] and macrocyclic [27] [28] transition state inhibitors and transition state mimics [29] . Importantly, in vivo proof of concept in a mouse model using a dipeptidyl transition state inhibitor of norovirus 3CLpro has also been demonstrated [25] . We describe herein the structure-guided exploration of the S 4 subsite of 3CLpro and the subsequent deployment of structure-activity relationship and biochemical studies in the design and discovery of potent and permeable inhibitors of the enzyme.
Results and Discussion

Inhibitor design rationale
The design and optimization of the inhibitors was informed by the utilization of available crystal structures and the parallel acquisition of additional high resolution X-ray crystal structures. Thus, inspection of previously-determined high resolution X-ray crystal structures of dipeptidyl inhibitors bound to norovirus 3CL protease (PDB accession codes 4XBB, 4XBC and 4XBD) [25] revealed that the "cap" R group in inhibitor (I) projects toward the S 4 subsite of the enzyme and suggested that its close proximity to a string of hydrophobic amino acids (Ala158, Ala160, Val168 and Ile109) can be exploited through appropriate cap modifications, including the use of sulfonamide functionalities. Additional design considerations included the use of key recognition elements, such as a Gln surrogate [30] and a cyclohexyl methyl residue at the P 1 and P 2 positions, respectively, capable of engaging in H-bonding and hydrophobic interactions. Finally, based on the recentlydemonstrated in vivo efficacy of aldehyde bisulfite adducts [31] , this moiety was incorporated into inhibitor (I) and, for comparative purposes, the corresponding aldehyde inhibitors were also included. esters 4a-m. Reduction with lithium borohydride generated the corresponding alcohols 5a-m. Dess-Martin periodinane oxidation of 5a-m proceeded smoothly to yield aldehydes 6a-m which were transformed to the corresponding aldehyde bisulfite adducts 7a-m. The synthesized sulfonamide derivatives are listed in Table 1 . Carbamates 12a-c were synthesized according to Scheme 2 via reaction of intermediate 3 with an appropriate chloroformate and further elaboration to yield the corresponding aldehydes and aldehyde bisulfite adducts, which are listed in Table 2 .
Biochemical Studies
The inhibitory activity of the synthesized compounds against NV 3CLpro and their antinorovirus activity in a cell-based replicon system, were evaluated as described in the experimental section [32] . The determined IC 50 , EC 50 and CC 50 values are listed in Tables 1  and 2 and they are the average of at least two determinations.
Inspection of the results in Table 1 permit the following inferences to be drawn: (a) the potency of the aldehyde bisulfite adducts is comparable to those of the precursor aldehydes, an observation noted previously [25, 33] . Advantages accrued through the use of aldehyde bisulfite adducts include higher solubility and metabolic stability, as well as low cytotoxicity [31] . Whether the bisulfite adducts exert their action by functioning as transition state mimics or latent precursors of the aldehyde functionality, or both, has not been established as yet and is currently under investigation; (b) a significant increase in potency (15-fold) was observed when the phenyl ring is moved further into the S 4 pocket (Table 1 , compare the EC 50 values of compounds 7a, 7b and 7c) and an additional 4-fold gain in potency was realized by extending the linker further (Table 1 , compound 7l). These observations are congruent with the results of X-ray crystallographic studies with inhibitor 7l. Crystallization of NV 3CLpro with inhibitor 7l yielded hexagonal and orthorhombic crystals and the electron density clearly shows the sulfur atom of the active site Cys139 residue bound covalently to the carbonyl carbon of the P 1 residue of inhibitor 7l, thereby establishing the mechanism of action of this class of inhibitors ( Figure 2) . The electrostatic surface representation shows the aryl ring to be optimally nestled in the hydrophobic S 4 pocket of the enzyme and engaged in hydrophobic interactions with Ile109, Val168, Ala160 and Ala159 ( Figure 3 ). Inhibitor 7l is bound to the active site of the enzyme via a network of hydrogen bonds in the manner of an antiparallel β-sheet and includes inhibitor backbone Hbonds with Gln110 and Ala158 which serve to position and orient the inhibitor correctly with respect to the catalytic residues (Figures 4 and 5) . Additionally, a H-bond with His30 serves to stabilize the tetrahedral adduct and two critical H-bonds involving the P 1 Gln surrogate ring oxygen with His157 and Thr134 are clearly evident; (c) halogen substitutions in the aromatic ring were generally beneficial (Table 1 , compounds 6d/7d, 6e/7e and 6g/7g); (d) potency also improved when a 4-biphenyl or 2-pthalimidoethane moiety was used (Table  1 , compounds 6j/7j and 6k/7k); (e) the significance of hydrophobic interactions involving R and the S 4 subsite was further probed by using an n-octyl chain cap, resulting in inhibitors displaying submicromolar ED 50 values (Table 1 , compounds 6m/7m). The structural determinants accounting for the higher potency of compounds 6m/7m were identified by obtaining a high resolution X-ray crystal structure of the NV 3CLpro:7m complex ( Figure  6 ). Inhibitor 7m adopts a binding mode in the active site similar to 7l (Figure 7 ) which is clearly evident from the superposition of the two inhibitors in the active site of the enzyme ( Figure 8 ). Furthermore, inhibitor 7m engages in identical H-bond interactions as inhibitor 7l (Figure 9 ), hence the comparable potencies. Importantly, the n-octyl chain encompasses the S 4 subsite and participates in hydrophobic interactions with the string of hydrophobic amino acids that make up the S 4 pocket (Figure 10 ). The importance of hydrophobic interactions is similarly evident in carbamate derivatives 11c/12c (Table 2) ; and, (f) an eight to ten-fold increase in potency was realized when the sulfonamide linkage was replaced by a carbamate moiety (Table 2 , compounds 11a/12a versus compounds 6h/7h in Table 1 ).
Conclusion
Structural, synthetic, biochemical, and cell-based studies have been employed to illuminate the S 4 subsite of NV 3CLpro and to gain insight and understanding into the significance and impact of hydrophobic interactions on pharmacological activity. In principle, further gains in potency can be realized through the use of constrained R moieties that mitigate the entropic penalty incurred in using long aliphatic chains. The results reported herein provide a sound framework and a solid foundation for conducting further studies aimed at identifying antinorovirus drug candidates.
Experimental section
General
Reagents and dry solvents were purchased from various chemical suppliers (Chem-Impex, Acros Organics, TCI America, Aldrich, and Bachem) and were used as obtained. Silica gel (230-450 mesh) used for flash chromatography was purchased from Sorbent Technologies (Atlanta, GA). Thin layer chromatography was performed using Analtech silica gel plates (Newark, DE). Visualization was accomplished using UV light and/or iodine. NMR spectra were recorded in CDCl 3 or DMSO-d 6 using a Varian XL-400 spectrometer and are reported relative to TMS (δ H = 0.00 ppm). Chemical shifts are reported in ppm and spin multiplicities are represented by the following signals: s (singlet), d (doublet), dd (doublets of doublet), t (triplet), q (quartet) and m (multiplet). Melting points were recorded on a Mel-Temp apparatus and are uncorrected. High resolution mass spectrometry (HRMS) was performed at the University of Kansas Mass Spectrometry lab using an LCT Premier mass spectrometer (Waters, Milford, MA) equipped with a time of flight mass analyzer and an electrospray ion source or in-house using a G6230B TOF MS (Agilent Technologies, Santa Clara, CA). The purity of the synthesized compounds was established using HPLC and was >95%.
washed with saturated NaHCO 3 (40 mL), followed by saturated NaCl (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to yield a yellowcolored oily product. Purification by flash chromatography yielded ester 2 as a white solid. 
Methyl (S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanamido)-3-((S
)
Synthesis of compound 3-
To a solution of compound 2 (10 mmol) in dry DCM (5 mL) was added 4M HCl in dioxane (10 mL) and the mixture was stirred for 2 h at room temperature. The solvent was removed and the residue was dried under high vacuum to yield the hydrochloride salt as a pale white solid. 
Methyl (S)-2-((S)-2-amino-3-cyclohexylpropanamido)-3-((S
Synthesis of compounds 4a
-m-To a solution of compound 3 (5 mmol) in dry DCM (20 mL) kept at 0 °C was added triethylamine (TEA) (1.3 mL,11 mmol, 2.2 eq) slowly with stirring. The appropriate sulfonyl chloride derivative (5.5 mmol, 1.1 eq) was added and reaction mixture was stirred for 12 h at 35 °C. The solvent was removed and the residue was dissolved in ethyl acetate (50 mL) and washed with water (2 × 25 mL). The ethyl acetate layer was further washed with saturated NaCl (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to yield a crude product. Purification by flash chromatography yielded esters 4a-m. 2-((S)-3-cyclohexyl-2-((phenylmethyl)sulfonamido) 
Methyl (S)-
Methyl (S)-2-((S)-2-((2-(3-chlorophenyl)ethyl)sulfonamido)-3-cyclohexyl propanamido)-3-((S)
-
Methyl (S)-2-((S)-3-cyclohexyl-2-(thiophene-2-sulfonamido)propanamido)-3-((S)
Methyl (S)-2-((S)-2-([1,1′-biphenyl]-4-sulfonamido)-3-cyclohexylpropan amido)-3-((S)
Methyl (S)-2-((S
Methyl (S)-2-((S)-3-cyclohexyl-2-(octylsulfonamido)propanamido)-3-((S)
Synthesis of alcohols 5a
-m-To a solution of ester 4 (5 mmol) in anhydrous THF (30 mL) was added dropwise lithium borohydride (2M in THF, 7.5 mL, 15 mmol), followed by absolute ethyl alcohol (15 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then acidified using 5% HCl and the pH was adjusted to ~2. Removal of the solvent left a residue which was taken up in ethyl acetate (100 mL) and the organic layer was washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield compounds 5a-m. 3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl) (4-methoxyphenoxy) 488.3143.
(S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((phenylmethyl
(S)-
(S)-3-cyclohexyl-2-((4-fluorophenyl)sulfonamido)-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 5d:
(S)-2-((3-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)
(S)-2-((4-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)
(S)-2-(((4-chlorophenyl)methyl)sulfonamido)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl
(S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(m, 2 H), 7.48 -7.56 (m, 1 H), 7.59 (d, J=6.18 Hz, 1 H), 7.71 -7.76 (m, 1 H), 8.22 (d
(S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((3-
(S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S
Synthesis of aldehydes 6a-m-Compound 5 (5 mmol) was dissolved in
anhydrous dichloromethane (50 mL) under a nitrogen atmosphere and cooled to 0 °C. DessMartin periodinane reagent (3.18 g, 7.5 mmol, 1.5 eq) was added to the reaction mixture with stirring. The ice bath was removed and the reaction mixture was stirred at room temperature for 3 h (monitoring by TLC indicated complete disappearance of the starting material). A solution of 10% aqueous sodium thiosulfate (20 mL) was added and the solution was stirred for 15 minutes. The aqueous layer was removed and the organic layer was washed with 10% aqueous sodium thiosulfate (20 mL), followed by saturated aqueous sodium bicarbonate (2 × 20 mL), water (2 × 20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The yellow residue was purified by flash chromatography using silica gel (methylene chloride/ethyl acetate/ methanol) to yield a white solid 6a-m. phenylethyl) 
(S)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(phenylsulfonamido)propanamide 6a:
(S)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((phenylmethyl)sulfonamido)propanamide 6b:
(S)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((2-
(S)-3-cyclohexyl-2-((4-fluorophenyl)sulfonamido)-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6d:
(S)-2-((3-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6e:
(S)-2-((4-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6f:
(S)-2-(((4-chlorophenyl)methyl)sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6g:
(S)-2-((2-(3-chlorophenyl)ethyl)sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6h:
(S)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(S)-2-([1,1′-biphenyl]-4-sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)
(S)-3-cyclohexyl-2-((2-(1,3-dioxoisoindolin-2-yl)ethyl)sulfonamido)-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6k:
(S)-3-cyclohexyl-2-((3-(4-methoxyphenoxy)propyl)sulfonamido)-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6l:
(S)-3-cyclohexyl-2-(octylsulfonamido)-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl
Synthesis of bisulfite adducts 7a-m-
To a solution of aldehyde 6 (5 mmol) in dry ethyl acetate (20 mL) was added absolute ethanol (12 mL) with stirring, followed by a solution of sodium bisulfite (540 mg; 5 mmol) in water (5 mL). The reaction mixture was stirred for 3 h at 50 °C and then allowed to cool to room temperature. The precipitate was vacuum filtered and the solid was thoroughly washed with absolute ethanol. The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated to yield a yellowish oil which was treated with ethyl ether (2 × 50 mL) to form a white solid. The white solid was stirred with ethyl ether (30 mL) and ethyl acetate (15 mL) for 5 minutes. Careful removal of the solvent using a pipette yielded compounds 7a-m. 
Sodium (2S)-2-((S)-3-cyclohexyl-2-(phenylsulfonamido)propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl
Sodium (2S)-2-((S)-3-cyclohexyl-2-((phenylmethyl)sulfonamido)propan amido)-1-hydroxy-3-((S)
-, 1 H), 7.51 (br. s., 1 H), 7.73 (d, J=8.98 Hz, 1 H), 7.97 (d, J=8.98 Hz, 1 H
Sodium (2S)-2-((S)-3-cyclohexyl-2-((2-phenylethyl)sulfonamido)propan amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl
Sodium (2S)-2-((S)-2-((3-chlorophenyl)sulfonamido)-3-cyclohexylpropan amido)-1-hydroxy-3-((S)
Sodium (2S)-2-((S)-2-((4-chlorophenyl)sulfonamido)-3-cyclohexylpropan amido)-1-hydroxy-3-((S)
Sodium (2S)-2-((S)-2-(((4-chlorophenyl)methyl)sulfonamido)-3-cyclohexyl propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl
6.83 Hz, 1 H), 3.74 (q, J=6.77 Hz, 1 H), 3.84 -3.99 (m, 1 H), 4.17 -4.38 (m, 1 H), 7.41 (br
Sodium (2S)-2-((S)-2-((2-(3-chlorophenyl)ethyl)sulfonamido)-3-cyclohexyl propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl
Sodium (2S)-2-((S)-2-([1,1′-biphenyl]-4-sulfonamido)-3-cyclohexylpropan amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl
Sdium (2S)-2-((S)-3-cyclohexyl-2-((2-(1,3-dioxoisoindolin-2-yl)ethyl)sulfon amido)propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl
Methyl (S)-2-((S)-3-cyclohexyl-2-undecanamidopropanamido)-3-((S
Synthesis of alcohols 10a
-c-To a solution of ester 9 (5 mmol) in anhydrous THF (30 mL) was added dropwise lithium borohydride (2M in THF, 7.5 mL, 15 mmol), followed by absolute ethyl alcohol (15 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was acidified with 5% HCl and the pH adjusted to ~2. Removal of the solvent left a residue which was taken up in ethyl acetate (100 mL).
The organic layer was washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield compounds 10a-c. 4.1.9. Synthesis of aldehydes 11a-c-Compound 10 (5 mmol) was dissolved in anhydrous dichloromethane (50 mL) under a nitrogen atmosphere and cooled to 0°C. DessMartin periodinane reagent (3.18 g, 7.5 mmol, 1.5 eq) was added to the reaction mixture with stirring. The ice bath was removed and the reaction mixture was stirred at room temperature for 3 h (monitoring by TLC indicated complete disappearance of the starting material). A solution of 10% aqueous sodium thiosulfate (20 mL) was added and the solution was stirred for another 15 minutes. The aqueous layer was removed and the organic layer was washed with 10% aqueous sodium thiosulfate (20 mL), followed by saturated aqueous sodium bicarbonate (2 × 20 mL), water (2 × 20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The yellow residue was purified by flash chromatography (silica gel/methylene chloride/ethyl acetate/methanol) to yield aldehydes 11a-c. 4.1.10. Synthesis of bisulfite adducts 12a-c-To a solution of aldehyde 11 (5 mmol) in dry ethyl acetate (20 mL) was added absolute ethanol (12 mL) with stirring, followed by a solution of sodium bisulfite (540 mg; 5 mmol) in water (5 mL). The reaction mixture was stirred for 3 h at 50 °C. The reaction mixture was allowed to cool to room temperature and then vacuum filtered. The solid was thoroughly washed with absolute ethanol and the filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated to yield a yellowish oil. The oily product was treated with ethyl ether (2 × 50 mL) to form white solid. The white solid was stirred with ethyl ether (30 mL) and ethyl acetate (15 mL) for 5 minutes. Careful removal of the solvent using a pipette yielded compounds 12a-c. 3-chlorophenethoxy) 
3-chlorophenethyl ((S)-3-cyclohexyl-1-(((S)-1-hydroxy-3-((S)
3-chlorophenethyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S
2-(benzyloxy)ethyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl
N-((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S
Sodium (2S)-2-((S)-2-(((
Sodium (2S)-2-((S)-3-cyclohexyl-2-undecanamidopropanamido)-1-hydroxy-3-((S
X-ray crystallographic studies. Crystallization and data collection
Purified norovirus 3CL Protease (NV 3CLpro) in 100 mM NaCl, 20 mM Tris pH 8.0 (11 mg/mL) was used for preparation of the inhibitor complexes. Stock solutions (100 mM) of each inhibitor were prepared in DMSO and added to NV 3CLpro by mixing 7 μL of the inhibitor (3 mM) with 243 μL (0.5 mM) of NV 3CLpro and incubating on ice for 1 hour. All crystallization experiments were conducted Compact Jr. (Rigaku Reagents) sitting drop vapor diffusion plates at 20 °C using equal volumes of protein and crystallization solution equilibrated against 75 μL of the latter. Hexagonal NV 3CLpro:7l (h) and orthorhombic crystals NV 3CLpro:7l (o) were obtained for the NV 3CLpro:7l complex in 2-3 days from the Index HT screen (Hampton Research) condition G5 (25% (w/v) PEG 3350, 100 mM Tris pH 8.5, 200 mM lithium sulfate) and Wizard 3-4 screen (Rigaku Reagents) condition A10 (20% (w/v) PEG 3350, 200 mM sodium thiocyanate) respectively. Crystals of the complex with inhibitor 7m (NV 3CLpro:7m) were also obtained from the Index HT G5 condition. Samples were transferred to a fresh drop composed of 80% crystallization solution and 20% (v/v) PEG 200 and stored in liquid nitrogen. X-ray diffraction data were collected at the Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6M pixel array detector.
Structure Solution and Refinement
Intensities were integrated using XDS [34, 35] via Autoproc [36] and the Laue class analysis and data scaling were performed with Aimless [37] . Structure solution was conducted by molecular replacement with Phaser [38] using a previously determined structure of inhibitor bound to NV 3CLpro (PDB: 3UR9) [32] as the search model. Each crystal form contained two molecules in the asymmetric unit. Structure refinement and manual model building were conducted with Phenix [39] and Coot [40] , respectively. Disordered side chains were truncated to the point for which electron density could be observed. Structure validation was conducted with Molprobity [41] and figures were prepared using the CCP4MG package [42] . Structure superposition was conducted with GESAMT [43] .
FRET protease assays
The FRET protease assay was performed by preparing stock solutions of the substrate (Edans-DFHLQ/GP-Dabcyl) and inhibitor in DMSO and diluting into assay buffer which was comprised of 20mM HEPES buffer, pH 8, containing NaCl (200 mM), 0.4 mM EDTA, glycerol (60%), and 6 mM dithiothreitol (DTT). The protease was mixed with serial dilutions of each compound or with DMSO in 25 μL of assay buffer and incubated at 37°C for 30 min, followed by the addition of 25 μL of assay buffer containing substrate. Fluorescence readings were obtained using an excitation wavelength of 360 nm and an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800; Biotec, Winoosk, VT) 1 h following the addition of substrate. Relative fluorescence units (RFU) were determined by subtracting background values (substrate-containing well without protease) from the raw fluorescence values, as described previously [25, [31] [32] . The dosedependent FRET inhibition curves were fitted with a variable slope by using GraphPad Prism software (GraphPad, La Jolla, CA) in order to determine the IC 50 values of the inhibitors.
Cell-based inhibition assays
The effects of each inhibitor on virus replication were examined in the NV replicon harboring cells (HG23 cells) [32] . Briefly, confluent and semi-confluent cells were incubated with medium containing DMSO (<0.1%) or each compound (up to 100 μM) for 48 h. After the incubation, total RNA was extracted and viral genome was quantitated with real-time quantitative RT-PCR (qRT-PCR). The EC 50 values were determined by GraphPadPrism software [32] .
Nonspecific cytotoxic effects
The cytotoxic dose for 50% cell death (CC 50 ) for each compound was determined for HG23 cells used in this study. Confluent cells grown in 96-well plates were treated with various concentrations (1 to 100 μM) of each compound for 72 h. Cell cytotoxicity was measured by a CytoTox 96 nonradioactive cytotoxicity assay kit (Promega, Madison, WI) and crystal violet staining. The in vitro therapeutic index was calculated by dividing the CC 50 by the EC 50.
Accession Codes
Coordinates and structure factors were deposited to the Worldwide Protein Data Bank (wwPDB) with the accession codes: NV 3CLpro-7l (h) (5T6D), NV 3CLpro-7l (o) (5T6F), and NV 3CLpro-7m (5T6G).
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